Efficacy and safety of pyrimethamine/sulfadiazine/folinate combination therapy for the treatment of toxoplasmosis

Efficacy and safety of pyrimethamine/sulfadiazine/folinate combination therapy for the treatment of toxoplasmosis - Efficacy and safety of pyrimethamine/sulfadiazine/folinate for the treatment of toxoplasmosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029112

Enrollment

122

Registered

2017-09-13

Start date

2017-09-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

toxoplasmosis

Interventions

Treatment of toxoplasmosis patients with pyrimethamine/sulfadiazine/folinate. 1. active ocular toxoplasmosis: 2-6 weeks 2. toxoplasma encephalitis/disseminated toxoplasmosis: 6~4 to 6 weeks after sy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Toxoplasmosis of the following disease type 1. active ocular toxoplasmosis 2. toxoplasma encephalitis/disseminated toxoplasmosis 3. pregnant toxoplasmosis 4. congenic toxoplasmosis

Exclusion criteria

Exclusion criteria: 1. HIV positive patients 2. patients who are allergic to pyrimethamine and/or sulfadiazine 3. patients with megacytic anemia due to folic acid deficiency 4. patients who did not agree to join the study

Design outcomes

Primary

Measure	Time frame
Ocular toxoplasmosis: improvement of visual disorder 24 weeks after the end of therapy Encephalitis/disseminated toxoplasmosis: survival rate 4-6 weeks after the therapy Toxoplasmosis in pregnancy: congenital infection of the newborn Congenital toxoplasmosis: mental/motor retardation 3 years after birth	—

Countries

Japan

Contacts

Public ContactMaruyama Haruhiko

University of Miyazaki, Faculty of Medicine Department of Infectious Diseases

hikomaru@med.miyazaki-u.ac.jp0985-85-0990

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026